ERBB2 and breast cancer: The HER2-low subgroup, defined as IHC 1 + or IHC 2 + ISH −, comprises 50–55% of all BC patients and constitutes therefore a numerically large and significant group of patients (Gampenrieder et al. 2021; Schalper et al. 2014).